Skip to main
MYGN
MYGN logo

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 18%
Hold 55%
Sell 9%
Strong Sell 0%

Bulls say

Myriad Genetics Inc. is expected to experience a solid upward trajectory in its revenue, with projected growth of 6% year-over-year for 2026, primarily driven by a 10% increase in Prenatal testing and mid-single digit growth across other divisions such as Hereditary Cancer Testing and Pharmacogenomics. The company’s strategic launch initiatives in the oncology segment, including the introduction of Precise MRD and MyRisk with RiskScore, are poised to enhance its portfolio and potentially boost market share over the next 12-18 months. Additionally, strong test volume growth across various testing services underscores a favorable outlook for sustained business expansion in the evolving molecular diagnostics landscape.

Bears say

Myriad Genetics Inc. has recently experienced a downgrade to Sector Perform, alongside a reduction in the price target to $6, indicating a decline in investor confidence. This outlook may reflect underlying concerns regarding the company's growth potential and competitive position within the molecular diagnostics market. Additionally, the consistent reiteration of the downgraded stance suggests a persistent evaluation of challenges facing the company's financial performance.

Myriad Genetics (MYGN) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 18% recommend Buy, 55% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 11 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.